NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural ...
Medscape12h
Does Taking ‘The Pill’ Reduce Ovarian Cancer Risk?
The researchers found that having ever used oral contraception reduced odds of ovarian cancer by 26% (odds ratio [OR], 0.74; ...
STAT16h
The ironic origin story behind Sloan Kettering
Sloan Kettering is one of the world’s leading cancer centers. It was founded by two men who created and sold leaded gasoline ...